What is Hummingbird Bioscience?
Founded in 2015 and headquartered in Texas, Hummingbird Bioscience is dedicated to advancing precision therapies aimed at improving patient outcomes for difficult-to-treat conditions. The company's focus on hard-to-drug targets positions it at the forefront of innovative drug development within the competitive biotech landscape. The substantial capital raised indicates a strong market belief in its therapeutic approach and pipeline.
How much funding has Hummingbird Bioscience raised?
Hummingbird Bioscience has raised a total of $275M across 3 funding rounds:
Series B
$25M
Series C
$125M
Series C
$125M
Series B (2020): $25M with participation from Delian Capital, heritascapital.com, Mirae Asset Global Investments, GNTech Venture Capital, SK Holdings Co., Ltd., and SEED Capital
Series C (2021): $125M led by Novo Holdings, EDBI, Amgen Ventures, Frazier Healthcare Partners, and Octagon Capital
Series C (2025): $125M supported by Octagon Capital Group, Frazier Healthcare Partners, Altrium, Singapore Economic Development Board, Morningside Venture Capital, Ally Bridge Group, Novo Holdings, Polaris Partners, Droia, Pureos Bioventures, Affinity Asset Advisors, Amgen, and Edbi
Key Investors in Hummingbird Bioscience
Octagon Capital Group
Octagon Capital Group is a merchant banking firm specializing in investment banking services for high-potential companies, offering financings, M&A, and strategic advisory to enhance value across various sectors including pharmaceuticals and technology.
Frazier Healthcare Partners
Frazier Healthcare Partners is a private equity and venture capital firm focused on shareholder liquidity, incubation, and growth equity financing within the healthcare sector, established in 1991.
Altrium
Altrium is a technology firm specializing in Generative AI LLM solutions and enterprise APIs, partnering with Fortune 1000 companies and startups to deliver innovative software and accelerate business growth through cutting-edge technology.
What's next for Hummingbird Bioscience?
With its latest major strategic investment, Hummingbird Bioscience is poised for accelerated growth and the advancement of its clinical programs. This infusion of capital will likely support further research and development, clinical trial progression, and potential expansion of its therapeutic portfolio. The company's trajectory suggests a move towards later-stage development and potential commercialization, marking a critical phase in its evolution.
See full Hummingbird Bioscience company page
